Trevi Therapeutics, Inc. Operating Cash Flow
Trevi Therapeutics, Inc. (TRVI) reported Operating Cash Flow of -$34.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$17.43M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$16.69M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.63M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.88M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$42.09M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$38.26M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$31.71M.
- Trevi Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$28.18M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$34.12M 10-Q · filed 2026-08-06 | -$41.75M derived: sum of 3 quarters · filed 2026-08-06 | -$52.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$16.69M 10-Q · filed 2026-05-05 | -$24.32M derived: sum of 2 quarters · filed 2026-05-05 | -$35.20M derived: sum of 3 quarters · filed 2026-05-05 | -$45.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$18.51M derived: sum of 2 quarters · filed 2026-03-17 | -$28.61M derived: sum of 3 quarters · filed 2026-08-06 | -$42.09M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$10.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$20.98M derived: sum of 2 quarters · filed 2026-08-06 | -$34.46M 10-Q · filed 2025-11-13 | -$44.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$10.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$23.58M 10-Q · filed 2026-08-06 | -$33.13M derived: sum of 3 quarters · filed 2026-08-06 | -$42.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$13.48M 10-Q · filed 2026-05-05 | -$23.03M derived: sum of 2 quarters · filed 2026-05-05 | -$32.58M derived: sum of 3 quarters · filed 2026-05-05 | -$41.27M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$9.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$19.11M derived: sum of 2 quarters · filed 2026-03-17 | -$27.79M derived: sum of 3 quarters · filed 2026-03-17 | -$38.26M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$9.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$18.24M derived: sum of 2 quarters · filed 2025-11-13 | -$28.71M 10-Q · filed 2025-11-13 | -$35.06M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$8.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$19.15M 10-Q · filed 2025-08-07 | -$25.51M derived: sum of 3 quarters · filed 2025-08-07 | -$32.79M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$10.47M 10-Q · filed 2025-05-08 | -$16.83M derived: sum of 2 quarters · filed 2025-05-08 | -$24.11M derived: sum of 3 quarters · filed 2025-05-08 | -$33.98M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$13.64M derived: sum of 2 quarters · filed 2025-03-18 | -$23.51M derived: sum of 3 quarters · filed 2025-03-18 | -$31.71M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$7.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$17.15M derived: sum of 2 quarters · filed 2024-11-06 | -$25.35M 10-Q · filed 2024-11-06 | -$31.68M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$9.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$18.07M 10-Q · filed 2024-08-08 | -$24.40M derived: sum of 3 quarters · filed 2024-08-08 | -$32.98M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$8.20M 10-Q · filed 2024-05-07 | -$14.53M derived: sum of 2 quarters · filed 2024-05-07 | -$23.10M derived: sum of 3 quarters · filed 2024-05-07 | -$29.28M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$14.91M derived: sum of 2 quarters · filed 2024-03-20 | -$21.08M derived: sum of 3 quarters · filed 2024-03-20 | -$28.18M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$14.75M derived: sum of 2 quarters · filed 2023-11-09 | -$21.84M 10-Q · filed 2023-11-09 | -$28.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$6.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$13.27M 10-Q · filed 2023-08-10 | -$19.50M derived: sum of 3 quarters · filed 2023-08-10 | -$26.74M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$7.09M 10-Q · filed 2023-05-11 | -$13.32M derived: sum of 2 quarters · filed 2023-05-11 | -$20.56M derived: sum of 3 quarters · filed 2023-05-11 | -$28.46M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$13.47M derived: sum of 2 quarters · filed 2023-03-16 | -$21.37M derived: sum of 3 quarters · filed 2023-03-16 | -$28.95M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$7.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$15.14M derived: sum of 2 quarters · filed 2022-11-10 | -$22.72M 10-Q · filed 2022-11-10 | -$31.64M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$15.48M 10-Q · filed 2022-08-11 | -$24.40M derived: sum of 3 quarters · filed 2022-08-11 | -$31.37M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$7.58M 10-Q · filed 2022-05-12 | -$16.50M derived: sum of 2 quarters · filed 2022-05-12 | -$23.47M derived: sum of 3 quarters · filed 2022-05-12 | -$31.91M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$15.89M derived: sum of 2 quarters · filed 2022-03-17 | -$24.33M derived: sum of 3 quarters · filed 2022-03-17 | -$29.00M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$6.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$15.40M derived: sum of 2 quarters · filed 2021-11-10 | -$20.08M 10-Q · filed 2021-11-10 | -$26.28M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$8.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$13.11M 10-Q · filed 2021-08-12 | -$19.31M derived: sum of 3 quarters · filed 2021-08-12 | -$27.05M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$4.67M 10-Q · filed 2021-05-13 | -$10.88M derived: sum of 2 quarters · filed 2021-05-13 | -$18.61M derived: sum of 3 quarters · filed 2021-05-13 | -$23.67M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$13.94M derived: sum of 2 quarters · filed 2021-03-25 | -$19.00M derived: sum of 3 quarters · filed 2021-03-25 | -$23.09M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$7.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$12.79M derived: sum of 2 quarters · filed 2020-11-12 | -$16.89M 10-Q · filed 2020-11-12 | -$21.62M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$9.16M 10-Q · filed 2020-08-13 | -$13.89M derived: sum of 3 quarters · filed 2020-08-13 | -$17.88M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$4.10M 10-Q · filed 2020-05-07 | -$8.83M derived: sum of 2 quarters · filed 2020-05-07 | -$12.82M derived: sum of 3 quarters · filed 2020-05-07 | -$18.43M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$8.72M derived: sum of 2 quarters · filed 2020-03-16 | -$14.34M derived: sum of 3 quarters · filed 2020-03-16 | -$18.29M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$9.60M derived: sum of 2 quarters · filed 2019-11-14 | -$13.56M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$5.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$9.56M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$3.95M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |